This review aims to provide a translational perspective on recent developments in heart
failure with preserved ejection fraction (HFpEF), linking mechanistic insights to potential …

New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …

Fibrosis is a pivotal player in heart failure development and progression. Measurements of
(markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with …

Galectin-3 (Gal-3) is a β-galactoside-binding protein belonging to the lectin family with
pleiotropic regulatory activities and several physiological cellular functions, such as cellular …

Abstract Background Galectins are β-Galactose binding lectins expressed in numerous cells
and play multiple roles in various physiological and cellular functions. However, few …

Alzheimer's disease (AD) is the most common cause of dementia and is characterized by the
deposition of extracellular aggregates of amyloid-β (Aβ), the formation of intraneuronal tau …

Atherosclerosis is a multifactorial chronic inflammatory arterial disease forming the
pathological basis of many cardiovascular diseases such as coronary heart disease, heart …

Heart failure (HF) with preserved ejection fraction (HFpEF) is currently the predominant form
of HF with a dramatic increase in risk with age. Low‐grade inflammation, as occurs with …

Cardiac remodelling refers to changes in left ventricular structure and function over time,
with a progressive deterioration that may lead to heart failure (HF) development (adverse …

The field of cardio-oncology has emerged in response to the increased risk of
cardiovascular disease (CVD) in patients with cancer. However, recent studies suggest a …